PRMT3 and rectal cancer: Our data suggest that elevated PRMT3 expression inversely associates with treatment response, overall survival, and progression‐free survival in neoadjuvant settings, positioning PRMT3 as a promising biomarker candidate for tailored neoadjuvant therapies in rectal cancer.